Search

Displaying results 3611 - 3620 of 8698 in total
  1. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C.

  3. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    [L32853] An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. … [L32853] Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder.

    Categories: Drugs for Urinary Frequency and Incontinence, Adrenergic beta-3 Receptor Agonists
  4. Drug

    Lomustine

    go.drugbank.com/drugs/DB01206
    ApprovedInvestigational

    An alkylating agent of value against both hematologic malignancies and solid tumors.

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    (+)-menthol

    go.drugbank.com/drugs/DB11344
    Approved

    Mixtures: BlueStop Max
  6. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    CA-170

    go.drugbank.com/drugs/DB15772
    Investigational

    CA-170 is a selective, small molecule inhibitor of PD-L1.

  8. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  9. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows for subcutaneous injections to take place once every three months.

  10. Drug

    PF-477736

    go.drugbank.com/drugs/DB12611
    Investigational

    PF-00477736 has been used in trials studying the treatment of Neoplasms.